No sector is more sensitive to narrative distortion than pharmaceuticals. When a model tells a patient, a prescriber, or a regulator that your drug is unsafe — based on a retracted study, an outdated label, a confusion with a different molecule, or a phantom adverse-event signal — the consequences are both a public-health risk and a commercial risk. Deep Narrative Intelligence is how pharma companies measure, trace, and correct these narratives before they reach the people who make treatment and regulatory decisions.
The safety narrative is existential
In pharma, the safety narrative is not one risk among many; it is the risk that subsumes all others. A drug's commercial viability, regulatory standing, and patient acceptance all rest on the perception — and the reality — of its safety profile. When an AI model distorts that profile, it does not create a minor inconvenience. It introduces a new vector of risk that operates at the speed of a chatbot query, reaches patients directly, and bypasses the medical-information channels that pharma companies have spent decades building. The question is not whether models will be asked about your drug — they already are — but whether what they say matches the approved label, the current evidence, and the regulatory status.
How models get drugs wrong
The errors in pharma DNI audits follow specific patterns. Retracted-study persistence: a model cites a study that was formally retracted, because the retraction notice has not propagated into the training data. Stale labels: the model describes side effects or indications from a previous version of the label, before a post-marketing update. Molecule conflation: the model confuses your molecule with a similar one in the same class, attributing the other's adverse-event profile to yours. Phantom signals: the model references an adverse-event signal or regulatory action that was investigated and dismissed, or never existed. Each of these is a narrative distortion that can change a treatment decision.
Don't know what AI says about you today?
A SetRecord audit queries supported AI models about your organisation and measures the gap with verifiable facts — within five business days.
The patient-facing risk
Patients increasingly ask AI models about their medications. "Is [drug] safe for long-term use?", "What are the side effects of [drug]?", "Can I take [drug] with [other drug]?" The answers they receive shape decisions about adherence, about whether to fill a prescription, about whether to raise concerns with their physician. A model that overstates risks — or understates them — interferes with the physician-patient relationship at scale. Unlike a single misleading news article, a model's answer is repeated identically to every patient who asks the same question, creating a uniform distortion that no individual physician can counteract.
The regulator-facing risk
Regulators are also users of AI models. A reviewer who asks a model for background on a molecule before an advisory committee meeting, or a health-technology-assessment body that uses model outputs as one input among many, may encounter the same distortions. A model that describes a regulatory status inaccurately — "approved in the EU" when the drug is only approved in the US, or "under investigation" when the investigation is closed — can create confusion in a regulatory process that depends on precision. DNI for pharma includes a regulator-facing interrogation panel: the questions a regulator or HTA body would ask, measured for accuracy against the current regulatory record.
Why pharma corrections require extreme precision
Correcting a pharma narrative is harder than correcting a consumer-brand narrative because the margin for error is narrower. A correction that says "our drug is safe" is useless; the correction must cite the specific approved indication, the specific safety profile as described in the current label, the specific regulatory status as of the current date. A correction that overstates safety is as dangerous as the original distortion — it creates a new liability. This is why pharma DNI corrections are co-developed with regulatory and medical-affairs teams, and why the persistence measurement cycle is longer: a correction must hold not just for 90 days but across regulatory review cycles that can span a year or more. SetRecord applies this precision standard in every pharma engagement, because in this sector, an imprecise correction is a new risk.
Designing a pharma DNI programme
A pharma DNI programme is structured around the product lifecycle. Pre-launch, the interrogation panel focuses on the mechanism, the trial evidence, and the anticipated indication — ensuring models describe the drug accurately before it reaches patients. Post-launch, the panel expands to include real-world evidence questions, post-marketing surveillance topics, and comparative queries against competitor drugs. The critical-claim error rate is tracked against a topic list defined jointly with medical affairs and regulatory affairs, and corrections are routed through the same review process as any other external communication. The AI Image Score is reported to the pharmacovigilance committee, because in pharma, narrative risk is patient risk.